By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SymBio Pharmaceuticals 

Toranomon 30 Mori Building
3-2-2 Toranomon Minato-ku
Tokyo    105-0001  Japan
Phone: 03-5472-1125 Fax: 03-5472-3054



Company News
SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The Patient-Controlled Pain Management Drug "SyB P-1501" 6/13/2016 7:50:22 AM
The Medicines Company (MDCO) And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS (Fentanyl Iontophoretic Transdermal System) In Japan 10/7/2015 12:04:24 PM
SymBio Pharmaceuticals Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma 3/6/2013 9:44:01 AM
SymBio Pharmaceuticals Announces Results Presented at American Society of Clinical Oncology 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 6/5/2012 8:51:00 AM
Onconova Therapeutics Inc. and SymBio Pharmaceuticals Complete License Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer 7/8/2011 9:55:56 AM
SymBio Pharmaceuticals Raises $24M in Series E 2/28/2011 7:10:59 AM
SymBio Pharmaceuticals and Eisai Company, Ltd. (ESALY.PK) to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia 9/7/2010 2:29:32 PM
Abeille Pharmaceuticals, Inc. Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries 3/15/2007 10:49:33 AM